<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369340</url>
  </required_header>
  <id_info>
    <org_study_id>P3P-PK-01-CH</org_study_id>
    <nct_id>NCT03369340</nct_id>
  </id_info>
  <brief_title>Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile, Pharmacodynamics, Safety and Tolerability of Four P3P Variants in Smoking Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized, crossover study to evaluate the
      pharmacokinetic (PK) profiles of four P3P variants, following a fixed puffing regimen and an
      ad libitum use period. In addition, pharmacodynamic (PD) effects (subjective effects and
      related behavioral assessments), as well as human puffing topography, will be evaluated, to
      provide further insights on product acceptance and product use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the proposed study is to evaluate the pharmacokinetic profiles of four P3P
      variants. Variants differing in Nicotine and flavor will be tested to identify which one
      would yield plasma nicotine concentrations similar to those achieved after smoking a
      cigarette. All of the subjects will initially use the 1 mg nicotine-containing product (P3P
      3). Subject will continue the study using the three 2 mg nicotine-containing products (P3P 1,
      P3P 2 and P3P 4) in a randomly assigned sequence.

      Two product use regimens: fixed puffing and ad libitum use will be applied to provide insight
      into nicotine absorption. The fixed puffing regimen with consistent use conditions across
      subjects will be applied in order to minimize variability. The 1 hour ad libitum use period
      will provide information on nicotine PK and product acceptance when subjects use the P3P
      according to their own puffing behavior which is closer to a real-world setting.

      Safety and tolerability will also be assessed throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A single-center, open-label, randomized, crossover study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Sponsor staff, Investigator, the subjects and the investigational site will be blinded to the randomization sequences until they are assigned. Subjects will not be informed of the complete sequence to which they have been assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma nicotine concentration-time profile</measure>
    <time_frame>Derived from multiple blood sampling pre- and post-product use (over 240 minutes post-product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the plasma nicotine concentration-time profile of four P3P variants from the fixed puffing regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration [Cmax]</measure>
    <time_frame>Derived from multiple blood sampling pre- and post-product use (over 240 minutes post-product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the maximum nicotine plasma concentration [Cmax] of four P3P variants from the fixed puffing regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the maximum nicotine concentration [Tmax]</measure>
    <time_frame>Derived from multiple blood sampling pre- and post-product use (over 240 minutes post-product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the time to maximum nicotine concentration [Tmax] of four P3P variants from the fixed puffing regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from start of product use (T0 fix) to 4 hours [AUCfix (0-4h)]</measure>
    <time_frame>Derived from multiple blood sampling pre- and post-product use (over 240 minutes post-product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the area under the plasma concentration-time curve of four P3P variants from the fixed puffing regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma nicotine concentration-time profile</measure>
    <time_frame>Derived from multiple blood sampling pre-, during and post-product use (up to 240 minutes post-ad libitum product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the plasma nicotine concentration-time profile of four P3P variants from the ad libitum use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma nicotine concentration [Cpeak]</measure>
    <time_frame>Derived from multiple blood sampling pre-, during and post-product use (up to 240 minutes post-ad libitum product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the Peak plasma nicotine concentration [Cpeak] of four P3P variants from the ad libitum use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma nicotine concentration [Tpeak]</measure>
    <time_frame>Derived from multiple blood sampling pre-, during and post-product use (up to 240 minutes post-ad libitum product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the time to peak plasma nicotine concentration [Tpeak] of four P3P variants from the ad libitum use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma nicotine concentration [Ctrough]</measure>
    <time_frame>Derived from multiple blood sampling pre-, during and post-product use (up to 240 minutes post-ad libitum product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the trough plasma nicotine concentration [Ctrough] of four P3P variants from the ad libitum use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average of plasma nicotine concentration from T0 ad lib to 1 hour [Caverage]</measure>
    <time_frame>Derived from multiple blood sampling pre-, during and post-product use (up to 240 minutes post-ad libitum product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the average of plasma nicotine concentration [Caverage] of four P3P variants from the ad libitum use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from start of product use (T0 ad lib) to 4 hours [AUCad lib (0-4h)]</measure>
    <time_frame>Derived from multiple blood sampling pre-, during and post-product use (up to 240 minutes post-ad libitum product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the area under the plasma concentration-time curve of four P3P variants from the ad libitum use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving for a cigarette during and after the fixed puffing regimen and ad libitum use period</measure>
    <time_frame>During and up to 4 hours post-product use on days 1, 2, 3 and 4</time_frame>
    <description>Measured on on a Visual Analogue Scale (VAS) of 0 (no craving) to 10 (strong craving).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinforcing effects of P3P use</measure>
    <time_frame>Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4</time_frame>
    <description>Measured with an adapted version of the modified Cigarette Evaluation Questionnaire (adapted mCEQ) following the ad libitum use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory parameters</measure>
    <time_frame>Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4</time_frame>
    <description>Measured with a Sensory Questionnaire (SQ) following the ad libitum use period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human puffing topography (HPT) parameters of four P3P variants during the fixed puffing regimen and the ad libitum use period.</measure>
    <time_frame>During fixed puffing and 1 hour ad libitum product use on days 1, 2, 3 and 4</time_frame>
    <description>Measure per-puff parameters and per-product use experience parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of P3P products used from the fixed puffing regimen and the ad libitum use period.</measure>
    <time_frame>Before and after product use, during fixed puffing and 1 hour ad libitum product use on days 1, 2, 3 and 4</time_frame>
    <description>Measure the weight difference of P3P before and after use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability during the study.</measure>
    <time_frame>Study duration (13 days)</time_frame>
    <description>Incidence of adverse events (AEs), serious adverse events (SAEs), Frequency of AEs, SAEs.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P 1</intervention_name>
    <description>Product 1: 2 mg of nicotine; no flavor</description>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_label>Product Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P 2</intervention_name>
    <description>Product 2: 2 mg of nicotine; flavor</description>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_label>Product Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P 3</intervention_name>
    <description>Product 3: 1 mg of nicotine; flavor</description>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_label>Product Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P 4</intervention_name>
    <description>Product 4: 2 mg of nicotine; flavor</description>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_label>Product Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subject has signed the Informed Consent Form (ICF) and is able to understand the
             information provided in the ICF.

          -  Subject is between 21 and 65 years old.

          -  Subject is Caucasian.

          -  Smoking, healthy subject as judged by the Investigator or designee based on available
             assessments from the screening period.

          -  Subject has been smoking at least 10 commercially available cigarettes per day at
             least for the last 4 weeks prior to Screening Visit. Smoking status will be verified
             based on a urinary cotinine test (cotinine â‰¥ 200 ng/mL).

          -  Subject has been smoking for at least the last 3 years prior to Screening Visit.

          -  Subject does not plan to quit smoking in the next 2 months after the Screening Visit.

        Exclusion criteria:

          -  Female subject is not pregnant or breastfeeding.

          -  Female subject does not use estrogen-containing hormonal contraception or hormone
             replacement therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CROSS Research</name>
      <address>
        <city>Arzo</city>
        <state>Ticino</state>
        <zip>6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine</keyword>
  <keyword>Reduced risk product</keyword>
  <keyword>Nicotine-containing product</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

